Tumour hypoxia is a marker of poor prognosis and failure of chemoradiotherapy in head and
neck squamous cell carcinoma (HNSCC), providing a strategy for therapeutic intervention in
this setting. To evaluate the utility of the hypoxia-activated prodrug evofosfamide (TH-302) in
HNSCC, we established ten early passage patient-derived xenograft (PDX) models of
HNSCC that were characterised by their histopathology, hypoxia status, gene expression,
and sensitivity to evofosfamide. All PDX models closely resembled the histology of the …